BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 16, 2007
 |  BioCentury  |  Emerging Company Profile

Neurotune: Linking brain and brawn

As the population ages, sarcopenia - loss of skeletal muscle mass - is an increasingly important unaddressed problem. Neurotune AG thinks neurotrypsin could serve both as a biomarker and therapeutic target for the disease and that its neurotrypsin inhibitors also may work in stroke, brain trauma and schizophrenia.

Neurotune CSO Peter Sonderegger led the group of researchers that discovered neurotrypsin in the mid-1990s while working in the biochemistry department at the University of Zurich, where he is still a professor.

Neurotrypsin is a synaptic serine protease that can destabilize synapses. Excess activity of the protease is the hallmark of sarcopenia, a disease that starts around age 50 and affects men and...

Read the full 546 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >